ecrin-mdr-crcClinical2012Fatty LiverSteatohepatitisColorectal CancerColorectal Neoplasmsfirst-line palliative treated, KRAS-Wild-Type, metastatic colorectal cancerFatty LiverSteatohepatitisColorectal CancerFirst-line Palliative Treated, Kras-wild-type, Metastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2119641Austria45-fluorouracilIrinotecanChemotherapyFolinic acid (Leucovorin)PlaceboKRAS-Wild-TypeMetforminCetuximabMetastatic colorectal cancerSteatosisLiver injuryECRIN MDRTerminatedfalseA Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated SteatosisThis multicenter randomized, placebo-controlled phase II study will enroll 132 first-line palliative treated subjects with metastatic KRAS wild type CRC. Subjects with histologically confirmed, KRAS wild-type CRC without previous chemo-therapy for metastatic disease will be screened for this study. Approximately 10 sites in Austria will participate in the study. Subjects will be randomized in a ratio of 1:1 into two groups.2012-04-152119641NCT015236392011-001010-34